Product Details
| Product Name:
Zoldonrasib |
CAS No.:
2922732-54-3 |
| Purity:
99.76% |
Supply Ability:
10g |
| Release date:
2026/06/16 |
Product Introduction
Bioactivity
| Name | Zoldonrasib |
| Description | Zoldonrasib (RMC-9805) is a mutant-selective covalent KRAS G12D inhibitor with oral activity and significant antitumor activity, inducing tumor cell apoptosis in preclinical models of various KRAS-mutant cancers. |
| In vitro | METHODS:eCT26 (KRASG12D/G12D) and KPCY 6499c4 (KRASG12D/+) cells were treated with Zoldonrasib (100 nM) for 48 h; cytokine levels were measured by cytokine array, and cell surface expression was detected by flow cytometry.
RESULTS: CXCL1 and GM-CSF were decreased, PD-L1 and PVR were decreased; CXCL10 and CCL17 were increased, MHC-I and MHC-II were increased in eCT26 (KRASG12D/G12D) and KPCY 6499c4 (KRASG12D/+) cells. [2] |
| In vivo | METHODS: To detect in vivo anti-tumor activity, Zoldonrasib (100 mg/kg) was orally administered to eCT26 (KRASG12D/G12D) xenograft tumor mice once a day for 4-8 days.
RESULTS: Zoldonrasib exhibits anti-tumor activity in the KRAS G12D xenograft model. [2] |
| Storage | Keep away from moisture,Store at low temperature,Keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 252.5 mg/mL (216.1 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (4.28 mM), Sonication is recommended.
|
| Keywords | KRAS G12D |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Daraxonrasib | Sildenafil citrate |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | GPCR Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2026-06-30 |
|
|
$1.00
|
VIP2Y
|
Shaanxi Cuikang Pharmaceutical Technology Co., Ltd.
|
2026-07-09 |
United States